Key Focus Area

Life Sciences

The Opportunity

Innovative treatment approaches that hold the promise to cure disease are oftentimes considered too risky and lack the necessary funding and resources. At the same time, the prevalence of autoimmune diseases and allergies are rising, and the five-year cancer survival rates are virtually unchanged from 20 years ago despite a four-decade war. In 2030, cancer is expected to surpass heart disease to become the leading cause of death in the United States.

Traditional funding mechanisms for scientific and medical research often consider innovative ideas and treatments too risky, and they face significant financial and organizational barriers. Promising new treatments can wither on the vine in pre-trial stages while the disease burden continues to grow. From our groundbreaking cancer immunotherapy institute to our efforts to uncover a cure for allergies, we aim to speed to market treatments with the potential to improve health outcomes, reduce healthcare costs, and save millions of lives.

Who We Work With

  • LOGO_SEAN PARKER INST VOICE_2LINE_DIG BLK
Beneficiaries
University of California San Francisco

Research at the Immunology Program at University of California San Francisco will expand the understanding of autoimmune disease mechanisms in order to develop new therapies to improve treatments and reduce costs.

Weill Cornell Medicine

Weill Cornell Medical College provides care to patients with voice disorders and supports research geared at improving our understanding of voice disorders and developing new therapies.

Cancer Research Institute

The Cancer Research Institute is the world's only nonprofit organization dedicated exclusively to harnessing the immune system's power to conquer all cancers.